ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥3,020.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥76.70B
Enterprise Value¥74.98B
Total Cash (Recent Filing)¥7.23B
Total Debt (Recent Filing)¥13.77B
Price to Earnings (P/E)11.0
Beta0.54
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)178.85
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance Sheet / Low LeverageMaterial deleveraging and expanding equity materially reduce financial risk and increase strategic optionality. A low debt base supports funding R&D, shields the company from reimbursement shocks, and enables capex or M&A without stressing liquidity over the medium term.
Consistent Multi-year Revenue GrowthSustained top-line expansion reflects persistent demand for core branded drugs and helps drive scale benefits. Stable revenue growth underpins recurring cash flows, supports reinvestment in pipeline and commercialization, and makes forecasting less reliant on one-off events.
Full Value-chain Branded Pharmaceuticals ModelControlling R&D, manufacturing and domestic commercialization preserves margin capture and allows proactive lifecycle management. Vertical integration strengthens competitive positioning versus pure-play developers and supports steady domestic revenue and pricing execution over time.
Bears Say
Volatile Operating And Free Cash FlowIrregular cash conversion reduces predictability for funding R&D, dividends, or strategic investments. Variability suggests sensitivity to working capital, timing of receipts/payments or investment cycles, increasing execution risk despite recent recovery.
Profitability And Earnings VariabilityFluctuating net income and ROE indicate episodic margin pressure or one-off items, complicating investor visibility into sustainable returns. Earnings inconsistency can constrain reinvestment planning and make long-term performance projections less reliable.
Revenue Tied To Domestic Reimbursement DynamicsHeavy dependence on Japan's reimbursement and pricing regime exposes revenues to policy shifts and price revisions. Limited disclosed scale of out-licensing or global partnerships reduces diversification and upside from non-domestic or milestone income.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥3020.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥76.70B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 76 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on May 07, 2026. The company reported ¥53.53 earnings per share for the quarter, beating the consensus estimate of N/A by ¥53.53.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥53.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.553%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---